| Literature DB >> 30463914 |
Mohammed A Aljama1, M Hasib Sidiqi1, Arjun Lakshman1, Angela Dispenzieri1, Dragan Jevremovic1, Morie A Gertz1, Martha Q Lacy1, Francis K Buadi1, David Dingli1, Eli Muchtar1, Amie L Fonder1, Suzanne R Hayman1, Miriam A Hobbs1, Wilson I Gonsalves1, Rahma Warsame1, Taxiarchis V Kourelis1, Yi Lisa Hwa1, Prashant Kapoor1, Nelson Leung1,2, Ronald S Go1, Robert A Kyle1, S Vincent Rajkumar1, Shaji K Kumar1.
Abstract
The plasma cell proliferative index (PCPI), determined by a slide technique or by flow cytometry, detects cells in the S phase of the cell cycle and is a useful prognostic tool in patients with plasma cell disorders such as multiple myeloma and amyloidosis. We conducted a retrospective review analyzing the prognostic effect of PCPI in 306 patients with smoldering multiple myeloma (SMM). Seventy-nine (26%) patients had an elevated PCPI (>0.5). An elevated PCPI predicted an inferior time to progression (median, 3.0 vs 7.1 years for those with a low PCPI; P = .0004). Within 24 months, the progression rate was significantly higher for patients with an elevated PCPI (49% vs. 20%; P < .0001). PCPI is a valuable tool in risk stratifying patients with SMM and identifies patients with earlier progression who may benefit from closer follow-up and consideration of early intervention trials.Entities:
Mesh：
Year: 2018 PMID： 30463914 PMCID： PMC6258920 DOI： 10.1182/bloodadvances.2018024794
Source DB: PubMed Journal: Blood Adv ISSN： 2473-9529